Endometrial cancer
P Morice, A Leary, C Creutzberg, N Abu-Rustum… - The Lancet, 2016 - thelancet.com
Endometrial cancer is the most common gynaecological tumour in developed countries, and
its incidence is increasing. The most frequently occurring histological subtype is …
its incidence is increasing. The most frequently occurring histological subtype is …
Ovarian cancer: a heterogeneous disease
M Kossaï, A Leary, JY Scoazec, C Genestie - Pathobiology, 2018 - karger.com
Ovarian cancer encompasses a collection of neoplasms with distinct clinicopathological and
molecular features and prognosis. Despite there being a variety of ovarian cancer subtypes …
molecular features and prognosis. Despite there being a variety of ovarian cancer subtypes …
Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a …
PM Morice, A Leary, C Dolladille, B Chrétien… - The Lancet …, 2021 - thelancet.com
Background Poly (ADP-ribose) polymerase (PARP) inhibitors have shown efficacy and
acceptable safety in a range of neoplasms, particularly in ovarian cancers. However, some …
acceptable safety in a range of neoplasms, particularly in ovarian cancers. However, some …
[HTML][HTML] Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer
K Moore, N Colombo, G Scambia, BG Kim… - … England Journal of …, 2018 - Mass Medical Soc
Background Most women with newly diagnosed advanced ovarian cancer have a relapse
within 3 years after standard treatment with surgery and platinum-based chemotherapy. The …
within 3 years after standard treatment with surgery and platinum-based chemotherapy. The …
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled …
RL Coleman, AM Oza, D Lorusso, C Aghajanian… - The Lancet, 2017 - thelancet.com
Background Rucaparib, a poly (ADP-ribose) polymerase inhibitor, has anticancer activity in
recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome …
recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome …
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Background Poly (ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian
carcinomas with homologous recombination deficiency. Along with BRCA1 and BRCA2 …
carcinomas with homologous recombination deficiency. Along with BRCA1 and BRCA2 …
[HTML][HTML] Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy
A León-Castillo, SM De Boer, ME Powell… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
PURPOSE The randomized Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in
Women With High-Risk Endometrial Cancer (PORTEC-3) trial investigated the benefit of …
Women With High-Risk Endometrial Cancer (PORTEC-3) trial investigated the benefit of …
Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study
HC Chung, W Ros, JP Delord, R Perets… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE KEYNOTE-158 (ClinicalTrials. gov identifier: NCT02628067) is a phase II basket
study investigating the antitumor activity and safety of pembrolizumab in multiple cancer …
study investigating the antitumor activity and safety of pembrolizumab in multiple cancer …
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised …
S Banerjee, KN Moore, N Colombo, G Scambia… - The Lancet …, 2021 - thelancet.com
Background There is a high unmet need for treatment regimens that increase the chance of
long-term remission and possibly cure for women with newly diagnosed advanced ovarian …
long-term remission and possibly cure for women with newly diagnosed advanced ovarian …
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200) …
E Pujade-Lauraine, K Fujiwara, JA Ledermann… - The lancet …, 2021 - thelancet.com
Background Most patients with ovarian cancer will relapse after receiving frontline platinum-
based chemotherapy and eventually develop platinum-resistant or platinum-refractory …
based chemotherapy and eventually develop platinum-resistant or platinum-refractory …